• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerus raises funds for phase III trial of Intercept red blood cell system

December 19, 2016 By Sarah Faulkner

Cerus raises funds for phase III trial of Intercept red blood cell systemCerus Corporation (NSDQ:CERS) said today that it exercised $10.8 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funds will go towards in vitro pathogen inactivation and red blood cell function studies in support of FDA licensure and manufacturing clinical trial materials for a phase III trial in the U.S.

Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites and leukocytes in donated blood.

“The exercise of these additional options reflects the substantial progress our team has made in just a few short months since initiating activities related to this important contract with BARDA,” chief scientific officer Dr. Laurence Corash said in prepared remarks. “We are working closely with the FDA to reach an agreement on the protocol design for our Phase III trial, and this additional funding ensures that we can begin preparing the necessary clinical trials materials to move forward quickly upon such agreement.”

The Intercept system has been used in Europe for over 10 years to inactivate pathogens in platelet and plasma components. Cerus also won FDA approvals for use of the Intercept system with platelets and plasma in 2014.

Last year, Cerus said its European phase III trial evaluating the Intercept system for red blood cells demonstrated positive results. The company said today that its plans to submit an application for CE Mark approval has been delayed, but that its European red cell study in chronic anemia has finished enrolling patients.

The Sparc trial, which is evaluating the Intercept system in patients with thalassemia major requiring chronic red blood cell transfusions, has enrolled its target 70 patients. Cerus said it anticipates the data from the Sparc trial will be available in time to support its expected product launch in Europe.

“Chronic anemia patients such as those with thalassemia major and sickle cell disease require more blood transfusions than almost any other patient group, putting them at elevated lifetime risk for exposure to existing and emerging pathogens,” chief medical officer Richard Benjamin said. “Our ability to provide safety and efficacy data generated by the chronic anemia study at the time of our anticipated product launch will be an important supplement to the clinical data already included for submission.”

Filed Under: Clinical Trials, Featured, Funding Roundup, Regulatory/Compliance, Wall Street Beat Tagged With: Cerus Corporation

IN CASE YOU MISSED IT

  • Biden’s COVID-19 response will make manufacturers busy
  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS